Grundium Acquires Visiopharm

InSphero AG Acquires PhenoVista Biosciences, Inc.

May 20, 2026

Healthcare Services

InSphero AG announced it has acquired PhenoVista Biosciences, Inc., a San Diego-based contract research organization specializing in high-content imaging and phenotypic assay technologies. The deal is intended to expand InSphero’s advanced 3D, cell-based assay and imaging capabilities and accelerate adoption of more predictive, human-relevant drug discovery and toxicology workflows.

Roche to Acquire PathAI to Expand AI-Powered Digital Pathology

May 7, 2026

AI & Machine Learning

Roche has entered into a definitive merger agreement to acquire PathAI, a US digital pathology and AI technology company. The deal is expected to close in the second half of the year and will integrate PathAI’s AISight image management system into Roche’s Diagnostics division.

Parexel Acquires Vitrana

May 1, 2026

Healthcare Services

Parexel announced it has acquired Vitrana, an AI-enabled, end-to-end pharmacovigilance (PV) technology platform. The acquisition expands Parexel’s patient safety capabilities by integrating Vitrana’s AI automation into Parexel’s PV services to improve accuracy, cycle times, and compliance; financial terms were not disclosed.

Lupin Acquires VISUfarma from GHO Capital

September 29, 2025

Healthcare Services

Lupin Limited, through its wholly owned subsidiary Nanomi B.V., signed a definitive agreement to acquire VISUfarma B.V. from healthcare investor GHO Capital Partners LLP. The acquisition expands Lupin’s specialty ophthalmology franchise by adding a portfolio of 60+ branded eye health products and established commercial operations across major European markets.

Optibrium Acquires BioPharmics LLC

August 31, 2023

Software

Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.

Vistagen Acquires Pherin Pharmaceuticals

December 21, 2022

Biotechnology

Vistagen (Nasdaq: VTGN) will acquire Pherin Pharmaceuticals in an all-stock transaction (approximately 12.4 million shares plus nominal cash), giving Vistagen full ownership of Pherin's pherine drug pipeline and intellectual property. The deal eliminates future royalty and milestone obligations related to PH94B and PH10 and adds three early-stage pherine candidates to Vistagen's development portfolio.